5-Amino-1MQ

5-Amino-1MQ is a metabolic research compound studied for how the body stores fat, burns energy, handles glucose, and regulates cellular metabolism.

It targets an enzyme called NNMT (nicotinamide N-methyltransferase). NNMT is involved in how cells process nicotinamide, NAD+ metabolism, methylation chemistry, and energy balance. When NNMT activity is elevated, research suggests it may be linked to fat storage, reduced metabolic flexibility, insulin resistance, and obesity-related dysfunction.

5-Amino-1MQ is studied for helping shift fat-cell metabolism away from storage and toward better energy use.

In practical terms, it is researched for fat metabolism, body composition, metabolic flexibility, insulin sensitivity pathways, NAD+ preservation, adipose tissue function, liver fat, and obesity-related metabolic dysfunction.

This is not a GLP-1 appetite suppressant, not a stimulant, and not a classic fat burner. It is studied for a deeper mechanism: inhibiting NNMT, an enzyme connected to how fat cells manage energy, methylation, and NAD+ availability. It should not be described as a proven human weight-loss drug, the strongest data is still preclinical.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT methylates nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine. Because NNMT interacts with nicotinamide, SAM, and NAD+-related pathways, it has become a research target in obesity, metabolic syndrome, type 2 diabetes, liver fat, cancer biology, inflammation, and age-related metabolic dysfunction.

Adipose tissue is an active endocrine and metabolic organ affecting insulin sensitivity, inflammation, hormone signaling, fuel storage, and energy expenditure. NNMT expression is increased in white adipose tissue and liver of obese and diabetic mice. A landmark Nature study showed NNMT knockdown in white adipose and liver protected mice against diet-induced obesity by increasing cellular energy expenditure and altered adipose SAM, NAD+, and polyamine metabolism.

5-Amino-1MQ was developed as a selective, membrane-permeable NNMT inhibitor. In preclinical research it reduced body weight, white adipose tissue mass, adipocyte size, and plasma total cholesterol in diet-induced obese mice, without significantly changing food intake, suggesting the mechanism is not appetite suppression.

Within Metabolic / Weight Loss, 5-Amino-1MQ sits on the adipose-metabolism and energy-expenditure side of the category. It differs from GLP-1 drugs (appetite, gastric emptying, glucose signaling) and from stimulants (short-term energy output). It is researched for changing the metabolic behavior of fat tissue via NNMT inhibition.

More recent preclinical research has combined NNMT inhibition with diet change, accelerating body weight and fat loss, improving lean-to-body-weight ratio, reducing liver and epididymal white adipose tissue weights, and improving hepatic steatosis vs. diet change alone. A 2024 study on 5A1MQ in diet-induced obese mice further supports NNMT inhibition as a research target in obesity and fatty-liver biology.

Strongest themes: NNMT inhibition, fat-cell metabolism, adipose tissue energy expenditure, NAD+/SAM preservation, body weight and fat mass reduction in obese mouse models, improved adipocyte size, improved insulin sensitivity pathways (preclinical), liver fat / hepatic steatosis research, and metabolic flexibility research.

Evidence is strongest in cell studies and animal models. Human clinical proof is not established. 5-Amino-1MQ should not be described as a proven weight-loss treatment, a proven fat-loss therapy, a proven metabolic medication, or a guaranteed body-composition tool for humans. The mechanism is interesting and the animal data justifies research interest, but human evidence is not strong enough to make clinical or consumer outcome claims.

5-Amino-1MQ should be presented as a metabolic research compound, not a proven weight-loss drug or dietary supplement. It is technically a small-molecule NNMT inhibitor, not a peptide, calling it a peptide is common in wellness marketing but not scientifically accurate.

FDA has issued a warning letter stating that drug products compounded using 5-Amino-1MQ were not eligible for 503B exemptions because 5-Amino-1MQ does not appear on the 503B bulks list and was not used to compound a drug on the drug shortage list.

Not FDA-approved for weight loss, fat loss, metabolic health, NAD+ support, anti-aging, obesity treatment, liver fat reduction, insulin sensitivity, or general wellness.

For tested athletes, 5-Amino-1MQ may present anti-doping risk under WADA S0 (substances not approved by a governmental regulatory health authority for human therapeutic use). Athletes subject to anti-doping rules should not assume it is permitted just because it is not always named in consumer-facing banned-substance summaries.

5-Amino-1MQ is a small-molecule NNMT inhibitor studied for adipose tissue metabolism, body composition research, fat mass reduction in preclinical models, NAD+ and SAM preservation, mitochondrial and cellular energy pathways, insulin sensitivity research, liver fat biology, obesity-related metabolic dysfunction, and metabolic flexibility.

5-Amino-1MQ is best positioned as a metabolic research compound involved in NNMT inhibition and fat-cell energy metabolism.

Its strongest practical relevance is the study of how fat cells regulate energy use, how NNMT influences NAD+ and SAM metabolism, how adipose tissue contributes to obesity-related dysfunction, and how NNMT inhibition may affect body weight, fat mass, insulin sensitivity, and liver fat in preclinical models.

The most accurate framing is metabolic and body-composition research, not guaranteed weight loss, appetite suppression, fat burning, obesity treatment, diabetes treatment, liver disease treatment, anti-aging, performance enhancement, or proven human body recomposition.